US 11,839,591 B2
Pharmaceutical combination for the treatment of melanoma
Veena Agarwal, Mumbai (IN); Giridharan Periyasamy, Bangalore (IN); Maggie Rathos, Mumbai (IN); Ankita Srivastava, Mumbai (IN); and Sreesha Srinivasa, Mumbai (IN)
Assigned to Piramal Enterprises Limited, Mumbai (IN)
Filed by Piramal Enterprises Limited, Mumbai (IN)
Filed on Feb. 5, 2021, as Appl. No. 17/168,876.
Application 17/168,876 is a continuation of application No. 14/904,407, granted, now 11,007,174, previously published as PCT/IB2014/063022, filed on Jul. 11, 2014.
Claims priority of provisional application 61/845,749, filed on Jul. 12, 2013.
Prior Publication US 2021/0393589 A1, Dec. 23, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4025 (2006.01); A61K 31/437 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/4025 (2013.01) [A61K 31/437 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 45/06 (2013.01)] 15 Claims
 
1. A pharmaceutical kit for the treatment of melanoma, the kit comprising a CDK (cyclin dependent kinase) inhibitor of Formula I, or a pharmaceutically acceptable salt thereof;

OG Complex Work Unit Chemistry
wherein Ar is 2 chloro-4-trifluoromethylphenyl; and a package insert comprising instructions directing the use of the CDK inhibitor in a combined treatment with a therapeutically effective amount of at least one anticancer agent selected from vemurafenib, dabrafenib, and trametinib.